AlphAIalphai — Financial news for AI agents
benzinga.comJUL 314 min read$MGRX

Mangoceuticals (MGRX) Stock Jumps 138% After Hours On Nuclear Reactor Deal: Here's Why It Is Trending Man

Mangoceuticals, Inc. (NASDAQ:MGRX) shares are trending on Thursday night. Shares of the public health and wellness company jumped 137.77% to $0.70 in after-hours trading on Thursday following the announcement of a definitive business combination with Nuclea Energy Inc., a developer of the Morpheus lead-cooled microreactor.

Original reporting
benzinga.com
Published Jul 31, 2026, 4:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 31, 2026, 5:00 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Mangoceuticals (MGRX) Stock Jumps 138% After Hours On Nuclear Reactor Deal: Here's Why It Is Trending Man — source image
Source · benzinga.com
Decision brief

The 30-second read

$MGRXBullishHigh
01

Why it matters

Traders are likely to reassess deal probability, conversion mechanics (one-for-one exchangeable shares), and the 19.99% ownership cap until approvals are obtained, driving volatility and momentum trading.

02

Market read

A definitive M&A-style combination announcement is driving a major after-hours move in a highly illiquid microcap, with approval and cap mechanics central to near-term trading risk.

03

What to watch

The article notes extreme volume and proximity to the 52-week low, so technical mean reversion and liquidity-driven swings could dominate near-term price action despite the headline deal.

Relevance 9/10Novelty 9/10Timing: after-hours Thursday, before/into next session

Background

Mangoceuticals announced a definitive business combination with Nuclea Energy involving a lead-cooled microreactor developer.

Company-level read

Ticker impact

$MGRXBullishHigh confidence
Context

Mangoceuticals shares jumped 137.77% after hours on a definitive business combination with Nuclea Energy, including a 19.99% ownership cap.

Expected impact

Elevated volatility likely persists into premarket as traders price deal probability, exchangeable-share conversion, and the 19.99% cap until approvals.

Evidence & confidence

The article attributes the outsized after-hours move directly to the definitive business combination announcement and provides concrete structural terms (amalgamation, exchangeable shares, and the ownership cap).

Market effects

Sector

Highlights continued capital-market activity in public health and wellness firms pivoting toward advanced nuclear/microreactor exposure.

Regional

No clear regional spillover beyond US microcap M&A sentiment.

Global

Nuclear microreactor deal framing may attract cross-border attention, but the article provides no direct global market linkage.

Counterpoint

What could challenge this read

The 19.99% ownership cap and required stockholder and Nasdaq approvals can cap upside and increase deal-break risk, making the initial spike potentially fragile.

Key entities

  • public_company
    Mangoceuticals, Inc.

    NASDAQ-listed public health and wellness company whose shares surged after announcing a definitive business combination with Nuclea Energy.

  • public_or_private_company
    Nuclea Energy Inc.

    Developer of the Morpheus lead-cooled microreactor, to become an indirect wholly owned subsidiary post-transaction.

  • venue_regulator
    Nasdaq

    Approval required for the transaction, per the deal terms described in the article.

Read at source← All news

Related articles

AUG 6
$MGRXMed

Why is Mangoceuticals stock surging today?

Mangoceuticals (MGRX) shares rose 31.9% pre-open to $0.5612 after its merger partner, Nuclea Energy, said it reached a regulatory and siting milestone via a memorandum of understanding to locate the Morpheus microreactor at Utah’s San Rafael Energy Lab. The MOU supports a planned business combination that remains subject to approvals, with earnings expected around Aug. 13.

investing.com3 min
AUG 6
$MGRXMed

Mangoceuticals (MGRX) Stock Jumps Over 49% After Hours: Here's Why Mangoceuticals Stock Jumps 49% After H

Mangoceuticals (MGRX) shares rose more than 49% after hours after the company said it signed an MOU with Nuclea Energy to explore siting a nuclear test reactor at Utah’s San Rafael Energy Lab to support Nuclea’s Morpheus microreactor. Mangoceuticals and Nuclea have a July 30 business combination agreement, pending approvals. MGRX received a 180-day Nasdaq bid-price extension to Feb. 1, 2027.

benzinga.com4 min
JUL 31
$MGRXMedAI 8/10

Mangoceuticals To Merge With Nuclea Energy, Advancing Nuclear Microreactor; Stock Up

Mangoceuticals (MGRX) signed a definitive deal to combine with Nuclea Energy to advance Nuclea’s Morpheus nuclear microreactor to public markets. Nuclea shareholders will receive exchangeable shares in a new Mangoceuticals subsidiary, exchangeable one-for-one into MGRX common stock, subject to Nasdaq limits. MGRX closed at $0.29, down 46.88%, after a $0.16 to $2.75 52-week range.

rttnews.com4 min
JUL 30
$MGRXMedAI 8/10

Mangoceuticals, Inc.: Mangoceuticals Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor Technology

Mangoceuticals (NASDAQ: MGRX) said it signed a definitive business combination agreement with Nuclea Energy to take Nuclea’s Morpheus lead-cooled microreactor public. A new Mangoceuticals subsidiary will amalgamate with Nuclea, with Nuclea shareholders receiving exchangeable shares. Closing is subject to Mangoceuticals and Nasdaq approvals, with rights capped at 19.99% until then.

finanznachrichten.de4 min
JUL 30
$MGRXMedAI 8/10

Nuclea Energy Inc: Nuclea Energy Enters Definitive Business Combination Agreement with Mangoceuticals, Establishing a Path to a Nasdaq Public Listing to Advance the Morpheus Microreactor

Nuclea Energy Inc. said it signed a definitive business combination agreement with Mangoceuticals, Inc. (NASDAQ: MGRX) to pursue a Nasdaq public listing for Nuclea. Nuclea shareholders will receive exchangeable shares tied to Mangoceuticals common stock, with former Nuclea holders owning about 96% and Mangoceuticals holders about 4% post-closing, subject to approvals and a 19.99% Nasdaq cap.

finanznachrichten.de4 min